



Timothy J. Kulis

COUNSEL

Boston

P +1 617 648 9236

Tim is counsel in our Boston office.

Tim specializes in the representation of emerging growth companies throughout their lifecycles as well as venture capital investors. He maintains a broad practice including representing life sciences companies in the biotechnology, pharmaceutical, medical device, diagnostics and healthcare IT industries as well as technology companies in the consumer internet, software, telecommunications and energy industries.

Tim's practice focuses on general corporate counseling, venture capital financings, public offerings, public company representation and mergers and acquisitions. His practice spans the entire corporate lifecycle, from formation through liquidity. He regularly counsels companies in equity and debt financing transactions, including both early-stage and late-stage venture financings. He has advised issuers and underwriters in dozen of capital market transactions, including in several initial public offerings.

Tim's representative company clients include Be Biopharma, Carbon Biosciences, DeepCure, GPR, Larkspur Biosciences, LightForce Orthodontics, Nubis

Communications, Osmoses, Photys Therapeutics, RIGImmune, Solu Therapeutics and Well. Tim also represents a number of prominent venture capital funds and institutional investors in their financing activities.

Prior to joining Gunderson Dettmer, Tim was a counsel in the corporate practice group at WilmerHale.

Credentials

EDUCATION

- Boston College Law School, J.D.
cum laude
- Boston College, B.A., Political Science
summa cum laude

BAR ADMISSIONS

- Massachusetts

ACHIEVEMENTS

- 2025 *Best Lawyers* in America: Ones to Watch, Corporate Law

Focus Areas

Corporate Governance & Strategy

Mergers & Acquisitions

Fund Investments in Companies

Seed, Venture and Growth Financings

Public Companies/Public Offerings

Initial Public Offerings (IPOs) & Direct Listings

Life Sciences

Related News & Insights

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Newleos Therapeutics Announces \$93.5M Series A for Next Generation Mental Health Therapies

FIRM NEWS

Gunderson Dettmer Announces Attorney Promotions

CLIENT NEWS

Sherlock Biosciences Acquired by OraSure Technologies

CLIENT NEWS

Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Target Cardiometabolic Diseases

CLIENT NEWS

Wellington Management Co-Leads \$215M Series B Financing of Metsera

CLIENT NEWS

Be Biopharma Announces \$82M Financing to Advance Gene Therapy

CLIENT NEWS

Regeneron Ventures Invests in Cell Therapy Company ArsenalBio

FIRM NEWS

Best Lawyers Recognizes 29 Gunderson Dettmer Attorneys in the 2025 Best Lawyers in America Guide

CLIENT NEWS

MassMutual Ventures Leads \$14M Series A Financing of Cultivo

CLIENT NEWS

MassMutual Ventures Leads Prove Identity \$40M Financing

CLIENT NEWS

Osmoses Announces \$11M Series Seed Led by Energy Capital Ventures

CLIENT NEWS

LightForce Orthodontics Announces \$80M Series D

